I wish as a scientist that IMU would provide more information in their releases, but it is hard to argue given the SP performance over the last few days that IMU's management doesn't understand their shareholders.
It is still very early days for IMU's CF33 VAXINIA program and nobody should be expecting miracles - at Phase 1 any signal of efficacy is welcome. If CF33 will turn out to be a commercial success or not is not something I can comment on, beyond the obvious that many companies have tried in this space and none have yet succeeded. I certainly hope IMU is the first - not only for their shareholders, but for the patients as we need every improvement we can get in treating cancer.
Ann: Impressive Bisantrene Phase 2 AML Clinical Results, page-94
-
- There are more pages in this discussion • 138 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.55 |
Change
-0.070(4.32%) |
Mkt cap ! $264.0M | |||
| Open | High | Low | Value | Volume |
| $1.62 | $1.65 | $1.54 | $145.6K | 91.60K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5700 | $1.55 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 296 | 1 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |